Cara Therapeutics Inc at JPMorgan Healthcare Conference (Virtual) Transcript
Welcome, everyone. We're continuing the 40th JPM conference. I'm one of the associates at the Smid-Cap biotech research team. My name is Daniel Wolle. I'm joined today by President and CEO, Chris Posner of Cara Therapeutics. If you want to ask questions, as a reminder, there is a big blue ask-a-question button you can submit that, and I can ask the questions to the question portal.
Without further ado, Chris?
Yes. Thank you, Daniel. It's really an exciting time for Cara Therapeutics. It's exciting as we transition to a fast-growing commercial stage company with an approved product in the U.S. and for late to mid-stage programs in the clinic. And I kind of embody that excitement. And for me personally, I was a Board member at Cara for 3 years and became CEO in November. And moving from the board to the CEO role was really an opportunity. I simply could not pass up given the confidence I have in the company
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |